Role of Rho-Kinase in the Pathogenesis of Coronary Hyperconstricting Responses Induced by Drug-Eluting Stents in Pigs In Vivo

Journal of the American College of Cardiology

Volumn 54, Issue 24, 2009, Pages 2321-2329

  Shiroto, Takashi ^a   Yasuda, Satoshi ^a   Tsuburaya, Ryuji ^a   Ito, Yoshitaka ^a   Takahashi, Jun ^a   Ito, Kenta ^a   Ishibashi Ueda, Hatsue ^b   Shimokawa, Hiroaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

inflammation; smooth muscle; stents; vasoconstriction

Indexed keywords

CYPHER; HYDROXYFASUDIL; PACLITAXEL; RAPAMYCIN; RHO KINASE; SEROTONIN; TAXUS EXPRESS 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; CORONARY ARTERY CONSTRICTION; DRUG ELUTING STENT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VIVO STUDY; INFLAMMATION; LEFT CORONARY ARTERY; MALE; MICROTHROMBUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; SWINE;

ANIMALS; CELLS, CULTURED; CONSTRICTION, PATHOLOGIC; CORONARY ARTERY DISEASE; CORONARY VESSELS; DRUG-ELUTING STENTS; PACLITAXEL; RHO-ASSOCIATED KINASES; SWINE;

EID: 70549095980     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.07.045     Document Type: Article

References (41)

1. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
2. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
3. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
4. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., and Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
5. Maekawa K., Kawamoto K., Fuke S., et al. Images in cardiovascular medicine. Severe endothelial dysfunction after sirolimus-eluting stent implantation. Circulation 113 (2006) e850-e851
6. Obata J.E., Kitta Y., Takano H., et al. Sirolimus-eluting stent implantation aggravates endothelial vasomotor dysfunction in the infarct-related coronary artery in patients with acute myocardial infarction. J Am Coll Cardiol 50 (2007) 1305-1309
7. Hofma S.H., van der Giessen W.J., van Dalen B.M., et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 27 (2006) 166-170
8. Kim J.W., Suh S.Y., Choi C.U., et al. Six-month comparison of coronary endothelial dysfunction associated with sirolimus-eluting stent versus paclitaxel-eluting stent. J Am Coll Cardiol Intv 1 (2008) 65-71
9. Togni M., Windecker S., Cocchia R., et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 46 (2005) 231-236
10. Kim J.W., Park C.G., Seo H.S., and Oh D.J. Delayed severe multivessel spasm and aborted sudden death after Taxus stent implantation. Heart 91 (2005) e15
11. Shimokawa H., and Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 25 (2005) 1767-1775
12. Liao J.K., Seto M., and Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol 50 (2007) 17-24
13. Shimokawa H., Ito A., Fukumoto Y., et al. Chronic treatment with interleukin-1β induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. J Clin Invest 97 (1996) 769-776
14. Katsumata N., Shimokawa H., Seto M., et al. Enhanced myosin light chain phosphorylations as a central mechanism for coronary artery spasm in a swine model with interleukin-1β. Circulation 96 (1997) 4357-4363
15. Shimokawa H., Seto M., Katsumata N., et al. Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res 43 (1999) 1029-1039
16. Miyata K., Shimokawa H., Kandabashi T., et al. Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo. Arterioscler Thromb Vasc Biol 20 (2000) 2351-2358
17. Kandabashi T., Shimokawa H., Miyata K., et al. Inhibition of myosin phosphatase by upregulated Rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1β. Circulation 101 (2000) 1319-1323
18. Oi K., Shimokawa H., Hiroki J., et al. Remnant lipoproteins from patients with sudden cardiac death enhance coronary vasospastic activity through upregulation of Rho-kinase. Arterioscler Thromb Vasc Biol 24 (2004) 918-922
19. Masumoto A., Mohri M., Shimokawa H., Urakami L., Usui M., and Takeshita A. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 105 (2002) 1545-1547
20. Mohri M., Shimokawa H., Hirakawa Y., Masumoto A., and Takeshita A. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J Am Coll Cardiol 41 (2003) 15-19
21. Takemoto M., Sun J., Hiroki J., Shimokawa H., and Liao J.K. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 106 (2002) 57-62
22. Axel D.I., Kunert W., Goggelmann C., et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96 (1997) 636-645
23. Levin A.D., Jonas M., Hwang C.W., and Edelman E.R. Local and systemic drug competition in drug-eluting stent tissue deposition properties. J Control Release 109 (2005) 236-243
24. Morishige K., Shimokawa H., Eto Y., et al. Adenovirus-mediated transfer of dominant-negative Rho-kinase induces a regression of coronary arteriosclerosis in pigs in vivo. Arterioscler Thromb Vasc Biol 21 (2001) 548-554
25. Scheller B., Speck U., Abramjuk C., Bernhardt U., Bohm M., and Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 110 (2004) 810-814
26. Hizume T., Morikawa K., Takaki A., et al. Sustained elevation of serum cortisol level causes sensitization of coronary vasoconstricting responses in pigs in vivo: a possible link between stress and coronary vasospasm. Circ Res 99 (2006) 767-775
27. Miyata K., Shimokawa H., Yamawaki T., et al. Endothelial vasodilator function is preserved at the spastic/inflammatory coronary lesions in pigs. Circulation 100 (1999) 1432-1437
28. Ishibashi-Ueda H., Yutani C., Kuribayashi S., Takamiya M., Imakita M., and Ando M. Late in-stent restenosis of the abdominal aorta in a patient with Takayasu's arteritis and related pathology. Cardiovasc Intervent Radiol 22 (1999) 333-336
29. Rikitake Y., Kim H.H., Huang Z., et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 36 (2005) 2251-2257
30. Tsutsui M., Shimokawa H., Tanaka S., et al. Endothelial Gi protein in human coronary arteries. Eur Heart J 15 (1994) 1261-1266
31. Schiff P.B., Fant J., and Horwitz S.B. Promotion of microtubule assembly in vitro by Taxol. Nature 277 (1979) 665-667
32. Heldman A.W., Cheng L., Jenkins G.M., et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 103 (2001) 2289-2295
33. Mackay D.J., and Hall A. Rho GTPases. J Biol Chem 273 (1998) 20685-20688
34. Subbaramaiah K., Hart J.C., Norton L., and Dannenberg A.J. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 and p38 mitogen-activated protein kinase pathways. J Biol Chem 275 (2000) 14838-14845
35. Wessely R., Blaich B., Belaiba R.S., et al. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery. Thromb Haemost 97 (2007) 1003-1012
36. Shimokawa H. Cellular and molecular mechanisms of coronary artery spasm: lessons from animal models. Jpn Circ J 64 (2000) 1-12
37. Finn A.V., Nakazawa G., Joner M., et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 27 (2007) 1500-1510
38. Seasholtz T.M., Majumdar M., Kaplan D.D., and Brown J.H. Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res 84 (1999) 1186-1193
39. Hiroki J., Shimokawa H., Higashi M., et al. Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J Mol Cell Cardiol 37 (2004) 537-546
40. Noma K., Rikitake Y., Oyama N., et al. ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J Clin Invest 118 (2008) 1632-1644
41. Kanazawa K., Suematsu M., Ishida T., et al. Disparity between serotonin- and acetylcholine-provoked coronary artery spasm. Clin Cardiol 20 (1997) 146-152